Aldeyra Therapeutics (NASDAQ:ALDX) is a clinical‐stage biopharmaceutical company headquartered in Lexington, Massachusetts, focused on the discovery, development and commercialization of novel small-molecule therapies for immune‐mediated diseases. Since its founding in 2011, Aldeyra has pioneered the development of aldehyde trap compounds designed to mitigate cellular damage caused by reactive aldehydes, a class of toxic compounds implicated in a range of inflammatory and autoimmune conditions. The company applies its proprietary chemistry platform to advance both ocular and systemic programs, targeting significant unmet medical needs.
The company’s lead candidate, reproxalap, is a topical small molecule in Phase 3 development for dry eye disease and allergic conjunctivitis. Reproxalap has demonstrated anti‐inflammatory activity by irreversibly binding reactive aldehydes, thereby reducing biomarkers associated with ocular surface inflammation. In addition to reproxalap, Aldeyra’s pipeline includes ADX‐629, an oral therapy in Phase 2 for asthma and chronic obstructive pulmonary disease, and ADX‐161, an immune modulator in preclinical development for systemic lupus erythematosus. Aldeyra also holds ADX-2191, a potential therapy for uveitis, which is administered via intravitreal injection and has completed early‐stage clinical trials.
Throughout its history, Aldeyra has conducted global clinical trials, enrolling patients across North America and Europe and engaging regulatory agencies in both regions. The company maintains strategic collaborations for manufacturing and development support, positioning it to scale production upon regulatory approvals. While Aldeyra pursues FDA and EMA guidance for key programs, it continues to expand its research pipeline through strategic licensing and in-house discovery efforts.
Leadership at Aldeyra is led by President and Chief Executive Officer Eric Scher, who brings over 25 years of experience in life science management, and Chief Scientific Officer Bruce D. Warden, Ph.D., an expert in aldehyde chemistry and drug discovery. The board and executive team draw from diverse backgrounds in pharmaceutical development, biotechnology investment and regulatory affairs, guiding the company’s mission to deliver transformative treatments for patients with inflammatory diseases.
